Cancer drugs give Roche a 2012 profit boost

Published on NewsOK Modified: January 30, 2013 at 2:25 am •  Published: January 30, 2013
Advertisement
;

The drug maker said its top-selling products MabThera/Rituxan, Herceptin and Avastin all performed strongly in 2012 as demand grew in all regions. Genentech, which is owned by Roche, makes those three best-selling cancer drugs in the world. Avastin, which had dipped in sales, was "back on the growth path" after its launch for ovarian cancer in Europe at the end of 2011 and was also helped by stronger sales in Japan, the company said.

And the company cited robust demand for its clinical laboratory products in 2012, with the diagnostics division, which launched several new instruments and devices, reporting a 4 percent rise in sales to 10.3 billion francs.

Roche posted an 11 percent rise in 2012 core earnings per share, which rose to 13.62 Swiss francs ($14.74) compared to 12.30 francs a year ago.

Shares in Roche closed Tuesday at 201.40 francs, up 8.5 percent already this year.